# A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

> **NCT06901531** · PHASE3 · RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
- Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
- Metastatic Gastric Adenocarcinoma or Cancer
- Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** zolbetuximab
- **DRUG:** Pembrolizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Folinic acid (leucovorin or local equivalent)
- **DRUG:** 5-fluorouracil (5-FU)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06901531
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06901531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06901531, "A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06901531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*